Combination of pre-transplant flow cytometry, WT1 expression, and NGS for MRD monitoring is potent in predicting the prognosis of AML receiving allogeneic transplantation

• DOI: 10.1007/s00277-025-06384-0
• Publication Date: 2025-04-28T08:49:45Z
• Authors: Jie Liu; Dan Guo; Hanxi Lian; Peiwen Ding; Xin Liu; Yanqiu Zhao; Huibo Li; Shengjin Fan
• Keywords: Hematology

Minimal residual disease (MRD) monitoring has been demonstrated to important in predicting prognosis acute myeloid leukemia (AML) receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the ideal time point and method remain unclear. Our study compared prognostic value of multiparameter flow cytometry (MFC)-based WT1 expression-based MRD a month before allo-HSCT [HSCT(-1 m)] after [HSCT(+ 1 m)], as well next generation sequencing (NGS)-based at HSCT(-1 m), HSCT(+ 3 6 months m) among 47 AML patients undergoing allo-HSCT. The status by all methods was proved superior indicator with significance for progression, that m). For NGS-based MRD, seemed be optimal detection point, supported discrimination capability relatively high sensitivity progression prediction. Moreover, our data showed each individual had some limitations prognosis; however, pre-transplant combination MFC, NGS could greatly increase (100%) identifying improve stratification. may provide insights into methodology following